Enveda Biosciences said Thursday it raised $150 million in Series D financing, doubling the cash it’s pulled in from venture capitalists this year to further its drug discovery. Its latest round was ...

French biotech (ABVX) has emerged as the most likely acquisition target among biotechs in 2026, significantly outpacing others, while liver drug developer Madrigal Pharmaceuticals (MDGL) has become ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage biotechs in the bunch. The analysts’ selections for the upcoming year span ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

“Biotech is making money again,” Mizuho Securities declared to cap off 2025. The sentiment was echoed across a handful of sector previews as analysts reflected on a turbulent year in life sciences.

When Sam Darnold threw his second interception Thursday night, there was no reason to believe the Seattle Seahawks could come back. The Los Angeles Rams had clearly been the better team. Darnold was ...

SAN JOSE — Zebra Technologies and bioMerieux reported to the state Employment Development Department their separate decisions to cut jobs in moves that will eliminate a combined 196 positions in San ...

Capstan Therapeutics’ sale this year for $2.1 billion, the highest price paid for a private early-stage biotech company since 2022, was a triumph for its founders at the University of Pennsylvania.

Healthcare and biotech stocks have had a rough run since the giddy heights of the Covid pandemic. But now could be the perfect time to consider investing in these beaten-down but high-growth sectors.

As 2025 comes to an end, it’s a good moment to take a look at what happened this year in biotech. Unlike years defined by one big breakthrough, 2025 felt more like a phase shift, where many trends ...